In Brief
Using whole-exome sequencing on prescreened multiplex consanguineous families, Alazami et al. describe the identification of 33 novel candidate genes for various neurogenetic conditions. Such families are rich sources for novel gene discovery.
INTRODUCTION
Neurogenetic disorders represent the largest category of Mendelian diseases in humans. They encompass a wide array of clinical presentations that range from the common e.g., intellectual disability (>1%) to the very rare, e.g., neurodegeneration with brain iron accumulation (one to three per 10 6 ) (Kalman et al., 2012; Maulik et al., 2011) . The highly prevalent involvement of the nervous system in many Mendelian disorders coincides with the observation that >80% of all human genes are expressed at some stage of brain development (Hawrylycz et al., 2012) and suggests that the brain is one of the most vulnerable organs to genetic perturbation. In fact high-resolution microarray analysis of the human genome reveals that intellectual disability is the common phenotypic denominator of genomic disorders that involve losses or gains of genes (Coe et al., 2012) . Variances in clinical presentation are a major obstacle in establishing a working molecular classification of neurological disease, because even where the clinical presentation is highly specific, genetic heterogeneity is the rule. In the setting of autosomal recessive neurogenetic disorders where parents are related, a homozygosity scan can serve as a guide to the underlying genetic cause even when the phenotype is atypical (Alkuraya, 2010) . Another major challenge in assigning a molecular classification is that many neurological disease genes have not been identified yet.
Novel disease gene discovery in this field has been tremendously abetted by next-generation sequencing, a tool with the capacity to, theoretically, unravel the genetic cause of all neurological diseases. This full theoretical potential has not yet been reached unfortunately, although the technology continues to evolve. For example, two large studies on the genetics of intellectual disability using whole-exome sequencing (WES) provided a yield of 16%-55%, and even though the collective sample size was >150, only seven novel genes were identified (de Ligt et al., 2012; Rauch et al., 2012) . In these studies, samples could not be enriched for novel gene discovery, and simultaneously the anticipated mutations were heterozygous, detection of which poses a challenge for the currently available sequencing technology (especially regarding insertions/deletions) (Harismendy et al., 2009) . The presence of these two obstacles likely hindered the authors' ability to obtain a higher yield. Thus, alternative/complementary approaches are required to facilitate the discovery of novel neurogenetic disease genes. In this study, we show that the analysis of the entire set of autozygous intervals per individual (the autozygome) in multiplex consanguineous patients, as a prescreen, can markedly increase the yield of WES to identify candidate genes not previously associated with disease. Even when known genes were identified using this approach, the phenotype was often sufficiently different to explain why the gene had been missed by the autozygosity filter. The 33 candidate disease genes we showcase in this study will augment the global hunt for the genetics of brain development and function.
RESULTS

Clinical Report
In total, 143 multiplex families met our inclusion criteria (a neurogenetic diagnosis, positive family history, consanguineous parents, and no candidates identified by autozygosity mapping). Intellectual disability was the most common clinical feature.
Other phenotypes that were also enriched included global developmental delay, autism, epilepsy, primary microcephaly, ataxia, and neurodegeneration. Table S1 summarizes the clinical features of the entire cohort.
Autozygosity Mapping Is a Powerful Enrichment Tool for Novel Candidate Gene Discovery As a prescreening step for each case, the regions of homozygosity (ROH), the telltale sign of shared ancestral haplotypes, were interrogated for disease genes that matched the patients' phenotype. These genes were prioritized for Sanger sequencing. If negative, or when no compelling disease genes were evident in the ROH, patient DNA was subjected to WES under the assumption that this will reveal a novel disease gene. This assumption fails, however, to account for certain scenarios. When disease genes within the ROH are examined for a likely candidate, it is possible that the clinical picture may sufficiently deviate from the classical phenotype ascribed to a particular gene such that the gene falls outside our consideration. Specifically, we list in Table 1 cases in which there was sufficient discrepancy between the classical and observed phenotypes that the respective genes were missed in the autozygosity mapping stage. Some phenotypes can even be considered unique rather than an expansion of a known phenotype.
A second reason why WES may reveal a known disease gene is that the causal mutation may lie within an ROH but fail to be detected, which is one of the known ''pitfalls'' of autozygosity mapping (Alkuraya, 2012) . Figure S1 captures the homozygosity pattern of a number of patients for whom the candidate ROH was missed, because it did not meet our ROH size cutoff, or it appeared to be shared by an unaffected member of the family, or the overlap of the gene with the ROH was not clearly discernible. One case (11DG0165) evaded detection due to the presence of a deep intronic mutation, which was later uncovered using RT-PCR. A third scenario for why WES may expose a known disease gene is that the gene was simply overlooked when searching for plausible candidates within an ROH. This occurred in 13DG1803 where TUSC3, a known intellectual disability gene, was not noticed during the prescreening stage. Further scenarios include incomplete clinical information at the time of analysis (as occurred with 09DG-00774 and 12DG0926) and poor description in the literature (discussed below). We emphasize, however, that cases of failed autozygosity map prescreening are the exception rather than the rule because they represent only 7.7% (11/143) of all cases and have reduced the hypothetical yield of WES in revealing candidate genes not associated with disease, or known genes with unique phenotypes, by only 2.2%.
WES Is a Powerful Novel Candidate Gene Discovery Tool in Neurogenetic Disorders
Consistent with our prescreening enrichment step, WES revealed 69 genes that were not known to the authors at the time of exome capture. Of these, 36 have since been published by either us or others (detailed in Table S1), leaving 33 candidate genes that are here reported. The phenotypes associated with these are described in Table 2 and include intellectual disability, autism, progressive cerebellar atrophy, primary microcephaly, brain atrophy and other malformations, and myopathy. Of these mutations, ten are truncating or located at splice sites. For the missense changes, we determined pathogenicity based on the in silico prediction of at least two established algorithms, as well as 3D modeling of wild-type and mutant residues whenever structure information on homologous proteins was available ( Figure S2 ). Our minimum threshold for assigning candidacy to a gene was that the variant had to be the only one to survive the stringent pipeline illustrated in Figure 2 . A total of 37 cases remain ''unsolved,'' some because more than one variant survived our filters. Table S1 lists these, and it is important to note that some of these variants may indeed represent bona fide novel disease genes.
In addition, WES revealed what appears to be phenotypes that have not been described for the respective genes in 16 cases (Table 1) . One striking example is case 10DG0672 in which we identified a previously reported homozygous mutation in NPC2, a known gene for Nieman-Pick disease. Neither the index nor his sibling had the typical presentation of progressive neurodegeneration or hepatosplenomegaly, thus making the diagnosis of Nieman-Pick nearly impossible on clinical grounds. Finally, WES also revealed mutations in known genes for cases with classical phenotypes, where the gene was missed either due to a pitfall in autozygosity mapping or incomplete phenotyping (nine cases, discussed above) or because the phenotype was not well described in the literature as in two instances. The first such instance is MGAT2-related dysmorphism, which had only been documented by a single photograph (CormierDaire et al., 2000) . The second instance involves CTSD, which was described as causing congenital neuronal ceroid lipofuscinosis when, in fact, the detailed description of the case was severe microlissencephaly and hyperekplexia, which is identical to the phenotype of our case 09DG00288 (Fritchie et al., 2009) . Overall, the yield of WES in our cohort was 105 out of 143 (73.4%).
Although we used autozygosity mapping coupled with WES, an alternative strategy is to simply use the mapping information provided by WES analysis. Although most autozygous regions can indeed be inferred by this second strategy, we had previously shown that the use of high-throughput genotyping results in cleaner ROH data with sharper overall resolution (Carr et al., 2013) .
3D Modeling of Missense Variants to Support
Pathogenicity 3D modeling was performed for selected gene products using the web-based homology modeling engine Phyre2 (Kelley and Sternberg, 2009 ). Four of the models were built with very high confidence and suggested a pathogenic nature for the identified mutations. In the case of TUBA3E, the model was built based on the structure of tubulin alpha-3E (PDB ID: 3EDL) (Tan et al., 2008) that shares 97% sequence identity with the TUBA3E gene product ( Figure S2A ). The R215C mutation changes the charge distribution on the surface of the protein. Although not participating in microtubule formation (Tan et al., 2008) , this site might be involved in the binding of microtubule to other proteins or cofactors. The structure of the gene product of TSEN15, human tRNA splicing endonuclease, has been solved by nuclear magnetic resonance (Song and Markley, 2007 ) (PDB ID: 2GW6). The conserved W76 is embedded inside the protein and is critical in protein folding ( Figure S2B ). Mutation of W76G would leave a void in the core of the protein and very likely lead to misfolded proteins. PTRH2 encodes peptidyl-tRNA hydrolase 2. The crystal structure of a domain of PTRH2 has been solved (PDB ID: 1QSR). The observed mutation at Q85 is located in the middle of a helix and forms a hydrogen bond with the side chain of T157 ( Figure S2C ). Mutation of Q85P would destabilize PTRH2 as it would disrupt the hydrogen bond. Furthermore, the mutation to a proline may cause a kink in the helix and distort the overall fold of the structure. Iron-sulfur cluster assembly 2, or ISCA2, was also modeled with the structure of its homolog of IscA from Thermosynechococcus elongates (PDB ID: 1X0G), which is a a2b2 heterotetramer. ISCA2 has modest sequence identity (27% to PDB ID: 1X0G) to the a chain of the IscA. However, Phyre2 predicted the same structural fold with 100% confidence. The protein is involved in the maturation of iron-sulfur proteins. According to the model, the G77S mutation occurs in a loop that is directly involved in iron-sulfur cluster binding by providing a chelating cysteine, C79 ( Figure S2D ). We speculate that such a mutation might affect the stability or flexibility of the loop and therefore interfere with its efficiency of binding to the iron-sulfur cluster.
DISCUSSION
Several attempts have been made in the recent past to accelerate the discovery of novel neurological disease genes. One of the earliest attempts was the high-throughput Sanger sequencing of all coding exons on the X chromosome in a large cohort of >200 families with suspected X-linked intellectual disability (Tarpey et al., 2009 ). In addition to the laborious nature of this approach, the yield was somewhat modest (three novel genes) partly because enrichment for novel gene discovery was not feasible, and also partly due to a large proportion of X-linked disease genes having already been established (de Brouwer et al., 2007) . High-resolution molecular karyotyping is a powerful tool to identify a large number of DNA gains and losses that are associated with various neurological phenotypes, but the yield is typically <15%, and it rarely identifies single genes due to the nature of the assay (Miller et al., 2010) . Morrow et al. used autozygosity mapping in nearly 90 consanguineous families with autism, followed by Sanger sequencing of candidate genes within the linked ROH, to identify five novel autism genes (Morrow et al., 2008) . The lower yield of that study likely originates from the use of conventional sequencing methods, coupled with the potentially non-Mendelian behavior of autism genes.
The advent of next-generation sequencing has revolutionized the search for Mendelian neurocognitive genes. Rauch et al. and de Ligt et al. studied >150 cases of intellectual disability using a trio-exome design, and, although that approach is compatible with identifying recessive disease genes, they only identified heterozygous de novo mutations, including seven novel genes (de Ligt et al., 2012; Rauch et al., 2012) . The known bias of current WES against heterozygous mutations, especially insertions and deletions, as well as the inability of the investigators to enrich their cohort for novel genes are likely explanations for the lower yield. In 2011, Najmabadi et al. reported the identification of 50 novel candidate genes (Najmabadi et al., 2011) . Although that study, similar to ours, combines autozygosity mapping with next-generation sequencing of candidate ROH, their cohort was not enriched for novel gene discovery. Consequently, there were numerous cases that, upon exome sequencing, identified a gene that was classically linked to the clinical presentation (as per their Table 1 ). More importantly, the pipeline used in that study did not strictly require that the candidate variant be the only one to survive filtering in that family; hence, 24 of their candidate genes (48%) were not the sole surviving variant. Of the remainder, one variant (HIST3H3) is present at sufficiently high frequency in our collection of 485 exomes to be excluded (allele frequency 0.0082).
Beyond our analytic pipeline, the candidacy of many of our candidate genes can be corroborated through other lines of evidence. In the case of INO80, KCTD3, GEMIN4, and ISCA2, each of these genes maps to the only shared haplotype genome-wide across multiple or extended multiplex families ( Figure S3 ). TUBA3E belongs to a family of proteins that are known to be involved in brain malformation syndromes including lissencephaly, which is present in the affected patient ( Figure S4 ) (Jaglin et al., 2009; Keays et al., 2007; Poirier et al., 2010) . As well, TSEN15 belongs to a family of proteins (t-RNA splicing endonucleases) that have been found mutated in patients with pontocerebellar hypoplasia and microcephaly, which is what we observed in our patient (Budde et al., 2008; Cassandrini et al., 2010; Namavar et al., 2011) . SPDL1 controls poleward movement of chromosomes along the mitotic spindles, analogous to many of the known primary microcephaly genes that are involved in mitotic spindle regulation (Barisic et al., 2010; Chen et al., 2014) ; our patient exhibits an extreme reduction in overall brain volume resulting in an almost empty skull ( Figure S4 ). ISCA2 is involved in mitochondrial protein maturation, and depletion of the protein results in massively swollen mitochondria that are devoid of cristae membranes (Sheftel et al., 2012) . This is consistent with the mitochondrial encephalopathy detected in our patient. Table 2 summarizes what is known of the 33 candidate genes and available evidence that supports candidacy.
We were unable to identify a causal mutation in 25.9% of cases. Many of these have two or more variants that remained after filtering (Table S1 ), leaving open the possibility that one of these surviving variants may indeed be causal. Some of these are strong candidates. For instance, case 11DG0375 with brain atrophy has the first reported null mutation in SNCG, which encodes synuclein-g, and, although a role in neurodegeneration has been suspected, such a role has remained elusive (GretenHarrison et al., 2010) . Similarly, TRIM4 is a member of a family of proteins that has been implicated in a number of neurological disorders (TRIM2 in Charcot-Marie-Tooth, TRIM32 in Limb-Girdle Muscular Dystrophy, and TRIM18 in Opitz-GBBB (a syndromic form of intellectual disability) (Balastik et al., 2008; Frosk et al., 2002; Quaderi et al., 1997) . Thus, the homozygous TRIM4 truncation we identified in 12DG2083 may prove causal if additional mutations in this gene are identified in the future.
Cases in which no variants survived our filters may harbor classes of mutations that either the sequencing technology or our analysis pipeline are biased against e.g., compound heterozygous mutations, X-linked mutations, or mutations involving introns, UTRs, regulatory elements, and repeats. Nonetheless, our study clearly shows the utility of our approach when applied in the right population. Our pipeline as mentioned here has been very successful historically. Many unpublished genes we highlighted as novel and disease causing at the time of data analysis were subsequently published and verified by others, and this lends weight to the candidacy of the genes we report here. Indeed, such reports appeared as recently as a few months from this submission, e.g., DIAPH1, PIGQ, and WWOX (Ercan-Sencicek et al., 2014; Mallaret et al., 2014; Martin et al., 2014) . This is also true for certain variants in ''unsolved'' cases where more than one variant remained, e.g., SLC13A5 (Thevenon et al., 2014) . Our aim in publishing these 33 candidate genes is to accelerate the discovery of other independent mutations, thereby confirming pathogenicity and assisting in genetic diagnosis. Scaling of our study is feasible given the availability of the appropriate patient samples and the dropping cost of sequencing technology, with the promise that all autosomal recessive neurogenetic disease genes can be mapped within the timeframe required by the global brain initiatives.
EXPERIMENTAL PROCEDURES Human Subjects
Consanguineous families with history of a neurological disorder were clinically evaluated and recruited for this study using a King Faisal Specialist Hospital and Research Center institutional-review-board-approved protocol (RAC# 2121053) with informed consent. All families were multiplex, and all parents were confirmed to be healthy. Pedigrees of families with the 33 candidate genes are given in Figure 1 . For each family, blood was collected in EDTA tubes from all available members, and families were only included if at least one affected individual was available for sampling. DNA was extracted from whole blood using standard protocols.
Autozygome-Guided Mutation Analysis
Genome-wide SNP genotyping and homozygosity mapping was performed using the AxiomGWH SNP Chip platform (Affymetrix). See Supplemental Information for more details. Genes known to cause a neurological disorder compatible with the patients' phenotype, and present within the autozygome,
Figure 1. Pedigrees of Families with Novel Candidate Genes following WES Analysis
The family ID is presented above each pedigree. A red box indicates the affected family member who was submitted for WES, and asterisks denote all the family members we had access to for confirming segregation.
were screened by PCR and Sanger sequencing. If no such genes existed, or if they did exist but were excluded by sequencing, exome capture was performed. In total, individuals from 143 families were exome sequenced, and these families formed the cohort for this study.
Exome Sequencing
Exome capture was performed using the TruSeq Exome Enrichment kit (Illumina). See Supplemental Information for more details. A summary of the quality control data for exome sequencing is provided in Table S2 .
Analysis of Exomic Variants
Exome-derived data were filtered according to the schematic in Figure 2 . See Supplemental Information for full details. Segregation was assessed for all surviving variants, using all family members we had access to (Figure 1 ).
ACCESSION NUMBERS
All variants within the 143 exomes in this study can be accessed through the following link (part of the Saudi Variome Database): http://shgp.kfshrc.edu. sa/bioinf/db/variants/dg/index.html. The likely pathogenic variants reported in this study have also been uploaded to ClinVar, and this section will be updated with the corresponding accession number.
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C Figure 2. Schematic of the Experimental Pipeline for This Study
A total of 143 multiplex consanguineous families with history of a neurological disorder were found negative for known disease genes following autozygome-guided analysis and were recruited for this study. The bar illustrates the breakdown based on the number of cases, whereas the pie chart is based on the number of distinct genes identified in the solved cases.
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